Capsugel® Dry-Powder Inhalation Capsule Portfolio

May 21, 2019
Capsugel – Now a Lonza Company

Sponsored Content

Dry-powder inhalation (DPI) technology offers a favorable drug development opportunity for respiratory or systemic drug delivery. Delivering a uniform dose in a portable, easy-to-use system, capsule-based DPI device is a simple and cost-effective way to deliver inhalable medication.

 

Dry-powder inhalation is a major drug delivery technology for the treatment of respiratory diseases and, increasingly, for systemic drug delivery. Providing a uniform dose in a portable, easy-to-use system, capsule-based dry-powder inhalers (DPIs) are a simple and cost-effective way to deliver medication by the pulmonary route.

 

Polymer science and engineering have opened a new era of functional development, which offers the potential for selecting the optimal capsule for different active pharmaceutical ingredients (APIs) and various inhalation devices. These capabilities also can be associated with a wider range of services.

 

Within the dry-powder inhalation application fields, Lonza offers a portfolio of high-quality capsule solutions based on different polymers, tailored to enable consistent and optimal release performance. Building on a history of innovation in polymer science and capsule engineering, the Capsugel® brand, now part of Lonza, offers a suite of HPMC and alternate polymer capsules for the pharmaceutical world.

 

To learn more on Capsugel® Dry-Powder Inhalation Capsule Portfolio, visit:

www.capsugel.com/biopharmaceutical-products/dpi-capsules

 

Contact Details

Company name: Capsugel® │Lonza Pharma & Biotech

Website: www.capsugel.com/biopharmaceutical-products/dpi-capsules

E-mail: solutions.emea@lonza.com